Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Circassia Pharmaceuticals ( (GB:NIOX) ) just unveiled an announcement.
NIOX Group plc, a company listed on the AIM market, has announced an update on its total voting rights following the exercise of share options by employees. The company’s issued share capital now stands at 417,826,185 Ordinary Shares, with no shares held in treasury. This update is significant for shareholders as it affects the calculations needed to determine their interest in the company under the FCA’s Disclosure and Transparency Rules.
The most recent analyst rating on (GB:NIOX) stock is a Hold with a £76.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.
Spark’s Take on GB:NIOX Stock
According to Spark, TipRanks’ AI Analyst, GB:NIOX is a Neutral.
Circassia Pharmaceuticals’ overall stock score is driven primarily by its strong financial performance, characterized by robust revenue growth and cash flow management. The technical analysis indicates a positive trend, though momentum is limited. The high P/E ratio suggests potential overvaluation, partially offset by a decent dividend yield.
To see Spark’s full report on GB:NIOX stock, click here.
More about Circassia Pharmaceuticals
Average Trading Volume: 729,074
Technical Sentiment Signal: Buy
Current Market Cap: £317.5M
See more data about NIOX stock on TipRanks’ Stock Analysis page.